Ken Burchfiel has been a Partner at Sughrue Mion for over 20 years, counseling and representing clients in litigation in federal district courts, the U.S. Patent and Trademark Office, and in appeals in the Federal Circuit, regional circuits, and the U.S. Supreme Court. He has extensive experience conducting complex litigation and interference proceedings, and has represented individual corporations, industry consortia, and U.S. government agencies. His current principal focus as a member of Sughrue's Pharma Litigation Group is Hatch-Waxman Act ANDA litigation involving drugs such as Lipitor®, Cymbalta®, Lyrica®, and Zithromax®.
Mr. Burchfiel has frequently testified as a patent law expert in federal court litigation on topics including patent infringement, the doctrine of equivalents, validity, double patenting, inventorship, interference procedure, prior invention, inequitable conduct, numerous aspects of patent office procedure, patent valuation, and legal malpractice, in cases involving biotechnology inventions (monoclonal antibodies, humanized antibodies, bovine growth hormone, human growth hormone, RNA interference), pharmaceuticals, and business methods and systems. He has also served as a consulting expert in mediation involving malpractice issues.
Mr. Burchfiel lectures on topics including U.S. patent protection for biosimilars, litigation strategies for generic drug manufacturers in Hatch-Waxman litigation, biotechnology and interference law, and developments including proposed patent opposition provisions. He is a member of the faculty of the Japanese Intellectual Property Association, and has taught CLE courses on patent law developments including the 2009 Biologics Price Competition and Innovation Act, the 1994 Uruguay Round Agreements Act, patent term extension, and the Japanese patent system.
He received his A.B., cum laude, from Amherst College and his J.D. from Cornell University.
Mr. Burchfiel is the author of of the Bloomberg BNA treatise Biotechnology and the Federal Circuit.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)